Published in Transplantation on January 27, 2005
Early change in proteinuria as a surrogate outcome in kidney disease progression: a systematic review of previous analyses and creation of a patient-level pooled dataset. Nephrol Dial Transplant (2010) 0.83
Long-term impact of pretransplant and posttransplant diabetes mellitus on kidney transplant outcomes. World J Surg (2011) 0.82
Model comparisons of competing risk and recurrent events for graft failure in renal transplant recipients. Clin J Am Soc Nephrol (2012) 0.76
Derivation of a Predictive Model for Graft Loss Following Acute Kidney Injury in Kidney Transplant Recipients. Can J Kidney Health Dis (2017) 0.75
Proteinuria 1 year after renal transplantation is associated with impaired graft survival in children. Pediatr Nephrol (2015) 0.75
Filtration Markers, Cardiovascular Disease, Mortality, and Kidney Outcomes in Stable Kidney Transplant Recipients: The FAVORIT Trial. Am J Transplant (2017) 0.75
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet (2010) 14.24
Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med (2009) 12.73
High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA (2005) 12.00
Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med (2008) 10.03
Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA (2004) 9.74
Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA (2011) 8.24
Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med (2012) 7.93
Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med (2005) 4.84
Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet (2003) 4.19
Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes. J Am Coll Cardiol (2012) 3.66
Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet (2004) 3.59
Outcome of patients with low-gradient "severe" aortic stenosis and preserved ejection fraction. Circulation (2011) 3.38
Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N Engl J Med (2010) 3.17
Incidence of end-stage renal disease in patients with type 1 diabetes. JAMA (2005) 3.01
Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med (2014) 2.90
Homocysteine-lowering and cardiovascular disease outcomes in kidney transplant recipients: primary results from the Folic Acid for Vascular Outcome Reduction in Transplantation trial. Circulation (2011) 2.62
Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med (2003) 2.56
High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. J Am Coll Cardiol (2008) 2.51
Renal replacement therapy for diabetic end-stage renal disease: data from 10 registries in Europe (1991-2000). Kidney Int (2005) 2.44
Reports of large immunosuppression trials in kidney transplantation: room for improvement. Am J Transplant (2004) 2.40
Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation (2008) 2.30
High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation (2003) 2.28
Glucose-free dialysis solutions: inductors of inflammation or preservers of peritoneal membrane? Perit Dial Int (2005) 2.28
The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol (2004) 2.26
Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J (2009) 2.21
A safe citrate anticoagulation protocol with variable treatment efficacy and excellent control of the acid-base status. Crit Care Med (2009) 2.20
Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study. J Am Coll Cardiol (2013) 2.18
Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA (2012) 1.99
Total cardiovascular disease burden: comparing intensive with moderate statin therapy insights from the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) trial. J Am Coll Cardiol (2009) 1.97
High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial. Circulation (2004) 1.97
Rosuvastatin in diabetic hemodialysis patients. J Am Soc Nephrol (2011) 1.85
Fasting plasma glucose and glycosylated hemoglobin in the screening for diabetes mellitus after renal transplantation. Transplantation (2009) 1.79
Pre-transplant inosine monophosphate dehydrogenase activity is associated with clinical outcome after renal transplantation. Am J Transplant (2004) 1.77
Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single-centre study. Nephrol Dial Transplant (2004) 1.75
Lipid-modifying therapies and risk of pancreatitis: a meta-analysis. JAMA (2012) 1.71
Patient-reported gastrointestinal symptom burden and health-related quality of life following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium. Transplantation (2006) 1.65
Impact of genetic polymorphisms in cytomegalovirus glycoprotein B on outcomes in solid-organ transplant recipients with cytomegalovirus disease. Clin Infect Dis (2009) 1.64
Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy. Circulation (2002) 1.60
Fractional excretions of albumin and IgG are the best predictors of progression in primary glomerulonephritis. Nephrol Dial Transplant (2010) 1.60
Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin. Eur Heart J (2007) 1.56
Prospective study on late consequences of subclinical non-compliance with immunosuppressive therapy in renal transplant patients. Am J Transplant (2004) 1.54
Insights on urinary NGAL obtained in a primary care setting. Clin Chim Acta (2012) 1.53
Prevention of cardiovascular disease in adult recipients of kidney transplants. Lancet (2011) 1.52
Electrocardiographic abnormalities and uremic cardiomyopathy. Kidney Int (2005) 1.51
International differences in dialysis mortality reflect background general population atherosclerotic cardiovascular mortality. J Am Soc Nephrol (2006) 1.49
Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels. Int J Cardiol (2013) 1.49
Recurrent Primary Focal Segmental Glomerulosclerosis Managed With Intensified Plasma Exchange and Concomitant Monitoring of Soluble Urokinase-Type Plasminogen Activator Receptor-Mediated Podocyte β3-integrin Activation. Transplantation (2015) 1.47
Employment of patients receiving maintenance dialysis and after kidney transplant: a cross-sectional study from Finland. Am J Kidney Dis (2011) 1.47
A tricontinental view of IgA nephropathy. Nephrol Dial Transplant (2003) 1.46
Gender-associated risk factors for cardiac end points and total mortality after renal transplantation: post hoc analysis of the ALERT study. Clin Transplant (2006) 1.43
The 'blood group O problem' in kidney transplantation--time to change? Nephrol Dial Transplant (2010) 1.42
The effect of sevelamer on the pharmacokinetics of cyclosporin A and mycophenolate mofetil after renal transplantation. Nephrol Dial Transplant (2004) 1.42
Safety of meglumine gadoterate (Gd-DOTA)-enhanced MRI compared to unenhanced MRI in patients with chronic kidney disease (RESCUE study). Eur Radiol (2012) 1.42
An update on renal replacement therapy in Europe: ERA-EDTA Registry data from 1997 to 2006. Nephrol Dial Transplant (2009) 1.39
Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am J Transplant (2004) 1.38
Nephrogenic fibrosing dermopathy: a novel, disabling disorder in patients with renal failure. Nephrol Dial Transplant (2004) 1.38
Canadian Society of Transplantation consensus guidelines on eligibility for kidney transplantation. CMAJ (2005) 1.33
Gastrointestinal side effects of mycophenolic acid in renal transplant patients: a reappraisal. Nephrol Dial Transplant (2007) 1.30
Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density. Nephrol Dial Transplant (2005) 1.29
Canadian Society of Transplantation: consensus guidelines on eligibility for kidney transplantation. CMAJ (2005) 1.26
Nonadherence with diet and fluid restrictions among adults having hemodialysis. J Nurs Scholarsh (2005) 1.22
Therapeutic monitoring of calcineurin inhibitors for the nephrologist. Clin J Am Soc Nephrol (2007) 1.21
Risk factors for cardiovascular events after successful renal transplantation. Transplantation (2008) 1.21
Phospholipase A2 enzymes, high-dose atorvastatin, and prediction of ischemic events after acute coronary syndromes. Circulation (2012) 1.21
Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis. Circulation (2013) 1.20
Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. Clin J Am Soc Nephrol (2011) 1.19
Immunogenicity of a standard trivalent influenza vaccine in patients on long-term hemodialysis: an open-label trial. Am J Kidney Dis (2009) 1.18
Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study. Nephron Clin Pract (2005) 1.15
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J (2016) 1.14
Circulating levels of proinflammatory cytokines and neutrophil-platelet aggregates in patients with coronary artery disease. Am J Cardiol (2005) 1.14
Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study. Transplantation (2011) 1.13
Association of left atrial volume with mortality among ESRD patients with left ventricular hypertrophy referred for kidney transplantation. Am J Kidney Dis (2010) 1.12
Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies). Transplantation (2011) 1.12
Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients. Clin Pharmacol Ther (2004) 1.12
Are we overestimating left ventricular abnormalities in end-stage renal disease? Nephrol Dial Transplant (2007) 1.11
Inflammatory biomarkers, death, and recurrent nonfatal coronary events after an acute coronary syndrome in the MIRACL study. J Am Heart Assoc (2013) 1.11
Potential and opportunities for use of recombinant lactic acid bacteria in human health. Adv Appl Microbiol (2004) 1.11
Organ donation after cardiac death: donor and recipient outcomes after the first three years of the Ontario experience. Can J Anaesth (2011) 1.10
Determinants of left ventricular mass and hypertrophy in hemodialysis patients assessed by cardiac magnetic resonance imaging. Clin J Am Soc Nephrol (2009) 1.09
Design and baseline characteristics of the simvastatin and ezetimibe in aortic stenosis (SEAS) study. Am J Cardiol (2007) 1.09